← Leaderboards
Kirk Seward
Mercator Medsystems, Inc.
$8,233,759
Attributed
$9,059,900
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,059,900 · 7
By mechanism
R44$6,780,654 · 2
R42$1,352,604 · 1
R41$517,733 · 2
R43$408,909 · 2
Top collaborators
- Armin Ernst3 shared
- Farouc Amin Jaffer1 shared
Others in their field
Top investigators on “Infusion Procedures”
- Myron S Cohen · Family Health International$91,263,426
- Wafaa M. El-Sadr · Columbia University Health Sciences$91,263,426
- Georgia D Tomaras · Fred Hutchinson Cancer Center$70,233,271
- Dan H. Barouch · Fred Hutchinson Cancer Center$63,804,365
- Lawrence Corey · Fred Hutchinson Cancer Center$58,962,452
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$58,962,452
Research focus
Infusion ProceduresCathetersSuccessBlood VesselsTranslatingStentsInnovationTissuesDrug Delivery SystemsPharmaceutical PreparationsClinical TrialsEffective TherapyTunica AdventitiaDevicesDesignSafetyDoseNeedlesRestenosisOperative Surgical ProceduresInflammationMorbidity - Disease RatePreventionEnrollment
Grant awards (13)
Preventing Post-Thrombotic Syndrome after Deep Vein Thrombosis with Perivascular Anti-Inflammatory Agent Delivery$1,095,555
R44 · FY2025 · HL · contact PI
Improved Sirolimus-Analog Adventitial Delivery to Enhance Outcomes in Below-the-Knee Peripheral Artery Disease$1,000,000
R44 · FY2025 · HL · contact PI
Preventing Post-Thrombotic Syndrome after Deep Vein Thrombosis with Perivascular Anti-Inflammatory Agent Delivery$1,636,379
R44 · FY2024 · HL · contact PI
Improved Sirolimus-Analog Adventitial Delivery to Enhance Outcomes in Below-the-Knee Peripheral Artery Disease$1,000,000
R44 · FY2024 · HL · contact PI
Preventing Post-Thrombotic Syndrome after Deep Vein Thrombosis with Perivascular Anti-Inflammatory Agent Delivery$299,678
R41 · FY2021 · HL · contact PI
Improved Adventitial Rapamycin Therapy for Peripheral Artery Restenosis$1,088,602
R44 · FY2014 · HL · contact PI
Improved Adventitial Rapamycin Therapy for Peripheral Artery Restenosis$960,118
R44 · FY2013 · HL · contact PI
Broncho-adventitial Drug Delivery: Paclitaxel for Bronchial Carcinoma$213,437
R42 · FY2013 · CA · contact PI
Broncho-adventitial Drug Delivery: Paclitaxel for Bronchial Carcinoma$463,075
R42 · FY2012 · CA · contact PI
Broncho-adventitial Drug Delivery: Paclitaxel for Bronchial Carcinoma$676,092
R42 · FY2011 · CA · contact PI
Improved Adventitial Sirolimus Therapy for Peripheral Artery Restenosis$217,409
R43 · FY2010 · HL · contact PI
Bronchio-adventitial Drug Delivery: Paclitaxel for Bronchial Carcinoma$218,055
R41 · FY2009 · CA · contact PI
Adventitial Paclitaxel to Delay Post-Intervention Dialysis Graft Stenosis$191,500
R43 · FY2007 · DK · contact PI